Roche wins second FDA label expansion for Alecensa in NSCLC
The US Food and Drug Administration (FDA) has granted a label expansion to Roche’s Alecensa (alectinib) as an adjuvant therapy for patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC). Alecensa was approved as a second …